RE:RE:RE:RE:RE:RE:RE:RE:RE:TH is dead money While there is a lot of opinion involved, there are also facts, the biggest of which is the fact that the FDA has granted TH the right to do a phase III trial and there are factual comparisons to others in the same situation. Even applying a large discount to TH, it stock still has no value in it for NASH. Management can and should apply themselves to closing thst huge gap. In fact, they should have spent 4-6 weeks at least doing that before going ahead with that dumpster fire of an offering.
jfm1330 wrote: That's the bottom line in all this, you don't know, you think. It's not a matter of knowing or a matter of real facts, it's a matter of thinking about the potential, hence of opinion.
I think they are undervaluated based on what I think will happen, but it's only my opinion, or my guess, maybe an educated guess at best, but still a guess. The thing is that it is also the position the management is in. Clinical trials exist for a reason, to prove that drug candidates are safe and efficacious. So if I am CEO of a biopharma company I can express my confidence in the outcome of trials, but there is a fine line between expressing confidence and making believe it is a sure thing. Every time I heard Levesque he came across as confident in the prospects of NASH and oncology, not only confident, but enthusiastic, but he concluded by saying that what they needed to do first was to inject patients in clinical trials.
ANALIAS00 wrote:
- If you know that SP is undervaluated knowing time will prove it, you must not wait and act asap. Be hungry.